Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov;495(1):354-360.
doi: 10.1134/S1607672920060022. Epub 2020 Dec 25.

Indirubin-3'-Oxime (IDR3O) Inhibits Proliferation of Osteosarcoma Cells in vitro and Tumor Growth in vivo Through AMPK-Activation and PGC-1α/TFAM Up-Regulation

Bing Fu  1 , Guorui Yin  2 , Ke Song  3 , Xiurui Mu  4 , Bo Xu  5 , Xubin Zhang  5
Affiliations

Indirubin-3'-Oxime (IDR3O) Inhibits Proliferation of Osteosarcoma Cells in vitro and Tumor Growth in vivo Through AMPK-Activation and PGC-1α/TFAM Up-Regulation

Bing Fu et al. Dokl Biochem Biophys. 2020 Nov.

Abstract

Osteosarcoma, a malignant tumor of bones, has very high incidence in adolescents and young people. The present study investigated the effect of indirubin-3'-oxime (IDR3O) derivative on proliferation of osteosarcoma cells in vitro and tumor growth in vivo. Changes in growth and induction of apoptosis in osteosarcoma cells were assessed using WST-8 and TUNEL staining assays. Treatment of MG63 and Saos‑2 cells with IDR3O inhibited proliferation, activated apoptosis and promoted AMPK-activation. In IDR3O treated MG63 and Saos‑2 cells PGC-1α (Peroxisome proliferator-activated receptor-γ coactivator-1α) levels were markedly promoted compared to control (untreated) cells. In the mice model osteosarcoma was induced by implantation of 2 × 106 MG63 cells on dorsal side subcutaneously. Then the experimental group of mice received IDR3O intra-peritoneally during 45 days. IDR3O-treatment suppressed tumor development significantly compared to control (untreated) group but didn't changed body weight. IDR3O inhibits osteosarcoma cell growth and activates apoptosis through AMPK dependent pathway. Therefore, IDR3O may be considered for treatment of osteosarcoma as it effectively arrests tumor growth in mice.

Keywords: Apoptosis; Chemotherapy; Malignant; Osteosarcoma; PGC-1; Phosphorylation.

PubMed Disclaimer

References

REFERENCES

    1. Hegyi, M., Semsei, A.F., Jakab, Z., Antal, I., Kiss, J., Szendroi, M., Csoka, M., and Kovacs, G., Good prognosis of localized osteosarcoma in young patients treated with limb-salvage surgery and chemotherapy, Pediatr. Blood Cancer, 2011, vol. 57, pp. 415–422. - DOI
    1. van Maldegem, A.M., Bhosale, A., Gelderblom, H.J., Hogendoorn, P.C., and Hassan, A.B., Comprehensive analysis of published phase I/II clinical trials between 1990–2010 in osteosarcoma and Ewing sarcoma confirms limited outcomes and need for translational investment, Clin. Sarcoma Res., 2012, vol. 2, p. 5. - DOI
    1. Chan, D.C., Mitochondria: dynamic organelles in disease, aging, and development, Cell, 2006, vol. 125, pp. 1241–1252. - DOI
    1. Neuzil, J., Dong, L.F., Rohlena, J., Truksa, J., and Ralph, S.J., Classification of mitocans, anti-cancer drugs acting on mitochondria, Mitochondrion, 2013, vol. 13, pp. 199–208. - DOI
    1. Yamada, S., Nomoto, S., Fujii, T., Kaneko, T., Takeda, S., Inoue, S., Kanazumi, N., and Nakao, A., Correlation between copy number of mitochondrial DNA and clinico-pathologic parameters of hepatocellular carcinoma, Eur. J. Surg. Oncol., 2006, vol. 32, pp. 303–307. - DOI

MeSH terms

LinkOut - more resources